165 related articles for article (PubMed ID: 22178944)
1. Low dose aspirin therapy decreases blood glucose levels but does not prevent type i diabetes-induced bone loss.
Coe LM; Denison JD; McCabe LR
Cell Physiol Biochem; 2011; 28(5):923-32. PubMed ID: 22178944
[TBL] [Abstract][Full Text] [Related]
2. Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity.
Coe LM; Lippner D; Perez GI; McCabe LR
J Cell Biochem; 2011 Sep; 112(9):2403-11. PubMed ID: 21538476
[TBL] [Abstract][Full Text] [Related]
3. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death.
Coe LM; Irwin R; Lippner D; McCabe LR
J Cell Physiol; 2011 Feb; 226(2):477-83. PubMed ID: 20677222
[TBL] [Abstract][Full Text] [Related]
4. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption.
Motyl KJ; Raetz M; Tekalur SA; Schwartz RC; McCabe LR
Am J Physiol Regul Integr Comp Physiol; 2011 May; 300(5):R1250-60. PubMed ID: 21346244
[TBL] [Abstract][Full Text] [Related]
5. Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice.
Motyl KJ; McCabe LR
J Cell Physiol; 2009 Feb; 218(2):376-84. PubMed ID: 18932203
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.
Coe LM; Tekalur SA; Shu Y; Baumann MJ; McCabe LR
J Cell Physiol; 2015 Aug; 230(8):1944-53. PubMed ID: 25641511
[TBL] [Abstract][Full Text] [Related]
7. Both spontaneous Ins2(+/-) and streptozotocin-induced type I diabetes cause bone loss in young mice.
Coe LM; Zhang J; McCabe LR
J Cell Physiol; 2013 Apr; 228(4):689-95. PubMed ID: 22886636
[TBL] [Abstract][Full Text] [Related]
8. Bone inflammation and altered gene expression with type I diabetes early onset.
Motyl KJ; Botolin S; Irwin R; Appledorn DM; Kadakia T; Amalfitano A; Schwartz RC; McCabe LR
J Cell Physiol; 2009 Mar; 218(3):575-83. PubMed ID: 19006181
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclosporin A on bone mineral metabolism in experimental diabetes mellitus in the rat.
Epstein S; Takizawa M; Stein B; Katz IA; Joffe II; Romero DF; Liang XG; Li M; Ke HZ; Jee WS
J Bone Miner Res; 1994 Apr; 9(4):557-66. PubMed ID: 8030444
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss.
Botolin S; McCabe LR
J Cell Physiol; 2006 Dec; 209(3):967-76. PubMed ID: 16972249
[TBL] [Abstract][Full Text] [Related]
11. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
[TBL] [Abstract][Full Text] [Related]
12. Amylin increases bone volume but cannot ameliorate diabetic osteopenia.
Romero DF; Bryer HP; Rucinski B; Isserow JA; Buchinsky FJ; Cvetkovic M; Liu CC; Epstein S
Calcif Tissue Int; 1995 Jan; 56(1):54-61. PubMed ID: 7796348
[TBL] [Abstract][Full Text] [Related]
13. Annatto-extracted tocotrienols improve glucose homeostasis and bone properties in high-fat diet-induced type 2 diabetic mice by decreasing the inflammatory response.
Shen CL; Kaur G; Wanders D; Sharma S; Tomison MD; Ramalingam L; Chung E; Moustaid-Moussa N; Mo H; Dufour JM
Sci Rep; 2018 Jul; 8(1):11377. PubMed ID: 30054493
[TBL] [Abstract][Full Text] [Related]
14. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Mulay SR; Gaikwad AB; Tikoo K
Chem Biol Interact; 2010 Apr; 185(2):137-42. PubMed ID: 20223228
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
16. Regulation of vitamin C transporter in the type 1 diabetic mouse bone and bone marrow.
Sangani R; Naime M; Zakhary I; Ahmad S; Chutkan N; Zhu A; Ha Y; Hamrick M; Isales C; Elsalanty M; Smith S; Liou GI; Fulzele S
Exp Mol Pathol; 2013 Dec; 95(3):298-306. PubMed ID: 23999113
[TBL] [Abstract][Full Text] [Related]
17. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.
Botolin S; Faugere MC; Malluche H; Orth M; Meyer R; McCabe LR
Endocrinology; 2005 Aug; 146(8):3622-31. PubMed ID: 15905321
[TBL] [Abstract][Full Text] [Related]
18. Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss.
Zhang Y; Li XL; Sha NN; Shu B; Zhao YJ; Wang XL; Xiao HH; Shi Q; Wong MS; Wang YJ
Bone; 2017 Apr; 97():222-232. PubMed ID: 28130181
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats.
Pan Y; Wang Y; Cai L; Cai Y; Hu J; Yu C; Li J; Feng Z; Yang S; Li X; Liang G
Br J Pharmacol; 2012 Jun; 166(3):1169-82. PubMed ID: 22242942
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
